The global prucalopride market is booming, with a projected CAGR of 7% reaching $900 million by 2033. Driven by rising IBS-C prevalence and generic drug launches, this in-depth analysis explores market size, key players (Takeda, Johnson & Johnson), regional trends, and future growth potential.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.
